Page 1

Syndax >> Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update May 11 , 2021 - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT - 101 trial of SNDX - 5613 achieved full count recovery bringing CR / CRh rate up to 23 % - Company on track to initiate pivotal Phase 2 portion of AUGMENT - 101 trial in 2Q21 - - Enrollment of 23 cGVHD patients in Phase 2 expansion cohort testing axatilimab at 1 mg / kg complete ; enrollment ongoing in pivotal AGAVE - 201 trial of axatilimab in cGVHD - - Company to host conference call today at 4:30 p.m. ET - WALTHAM , Mass . , May 11 , 2021 / PRNewswire / -- Syndax Pharmaceuticals , Inc. ( " Syndax , " the " Company " or " we " ) ( Nasdaq : SNDX ) , a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies , today reported its financial results for the first quarter ended March 31 , 2021. In addition , the Company provided a clinical and business update . " We are excited to provide an update on the positive interim Phase 1 data from the ongoing AUGMENT - 101 trial of SNDX - 5613 in patients with mixed lineage leukemia rearranged ( MLLr ) and nucleophosmin ( NPM1c ) mutant acute leukemias , " said Briggs W. Morrison , M.D. , Chief Executive Officer of Syndax . " As Dr. Eytan Stein indicated in his presentation , complete eradication of leukemia need not occur simultaneously with complete recovery of blood cell counts , and today we are able to share that two prior responders have advanced from complete response with incomplete platelet recovery ( CRP ) to a complete response ( CR ) . The benefit we observe in AUGMENT - 101 support our strong conviction that SNDX - 5613 has the potential to meaningfully shape the treatment paradigm for these patients who are in desperate need of improved therapeutic options . As previously announced , we have identified a candidate recommended Phase 2 dose ( RP2D ) and look forward to commencing the pivotal Phase 2 portion of the trial . " " In addition , we continue to make progress with axatilimab in patients with chronic graft versus host disease ( cGVHD ) . We are pleased to announce today that we have completed enrollment of 23 patients in the Phase 2 expansion portion of the Phase 1/2 trial . We look forward to sharing full updated results from the Phase 1/2 trial later this year , with top - line data from the ongoing pivotal AGAVE - 201 trial expected in 2023. Supported by emerging data , we firmly believe that axatilimab has the potential to benefit many of the more than 10,000 patients diagnosed with cGVHD in the U.S. each year . " Recent Progress and Anticipated Milestones SNDX - 5613 The Company today announced new data from the ongoing Phase 1 dose escalation portion of the Phase 1/2 AUGMENT - 101 trial of SNDX - 5613 , a highly selective oral menin inhibitor , in patients with MLLr and NPM1c mutant relapsed / refractory ( R / R ) acute leukemias . The new data reported today , showed two prior responders have improved from CRp to CR with no evidence of minimal residual disease ( MRD- ) . With the addition of these two patients , a total of 7/31 patients ( 23 % ) have achieved CR / CRh . Syndax previously announced positive data from the Phase 1 portion of the AUGMENT - 101 trial in April 2021 and hosted a conference call featuring Eytan M. Stein , M.D. , Assistant Attending Physician and Director , Program for Drug Development in Leukemia , Department of Medicine at Memorial Sloan Kettering Cancer Center . As of the data cutoff date , the overall response rate ( ORR ) among evaluable patients was 48 % ( n = 15 ) , with 67 % ( n = 10 ) of these responders achieving MRD- status , and four proceeding to receive stem cell transplant . The ORR in evaluable patients harboring an MLL - rearrangement ( n = 24 ) , was 54 % ( n = 13 ) , and in evaluable patients harboring an NPM1c mutation ( n = 7 ) , was 29 % ( n = 2 ) . Across all patients enrolled in the trial as of the data cutoff date ( n = 43 ) , SNDX - 5613 was generally well - tolerated , with no discontinuations due to treatment - related adverse events observed in heavily pretreated patients . Syndax remains on track to initiate the pivotal Phase 2 portion of the trial this quarter . Axatilimab Syndax today announced that enrollment is now complete in the Phase 2 expansion portion of the Phase 1/2 trial of axatilimab , its anti - CSF - 1R monoclonal antibody , in patients with cGVHD . The Company anticipates reporting updated results later this year for 40 patients , including the 17 in the Phase 1 portion and 23 from the Phase 2 expansion portion , which evaluated 1 mg / kg of axatilimab every two weeks . Syndax reported preliminary data from the Phase 1 portion of the trial during an oral presentation at the American Society of Hematology Annual Meeting in December 2020 which highlighted the tolerability and high response rate of axatilimab in cGVHD patients refractory to multiple therapeutic agents . The Company's pivotal Phase 2 AGAVE - 201 trial of axatilimab in patients with cGVHD is ongoing , with topline data expected in 2023. The trial will evaluate the safety and efficacy of three doses and schedules of axatilimab . The primary endpoint will assess objective response rate based on the 2014 NIH consensus criteria for cGVHD , with key secondary endpoints including duration of response and improvement in modified Lee Symptom Scale score . Earlier this year , the Company announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to axatilimab for the treatment of patients with cGVHD and idiopathic pulmonary fibrosis . First Quarter 2021 Financial Results As of March 31 , 2021 , Syndax had cash , cash equivalents and short - term investments of $ 271.3 million and 51.6 million shares and share equivalents issued and outstanding . This includes 3.3 million pre - funded warrants .